Clinical trials: Atorvastatin
Effect of Atorvastatin on the Pharmacokinetics of Lomitapide
Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.
The primary objective of this study is to assess the effect of atorvastatin, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and its 2 primary metabolites, M1 and M3.
- Trial name
- NCT02080455
- Testing
- lomitapide, Atorvastatin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Aegerion Pharmaceuticals, Inc.